WO2011002856A2 - Method for neutralization of antibiotics in a culture medium - Google Patents
Method for neutralization of antibiotics in a culture medium Download PDFInfo
- Publication number
- WO2011002856A2 WO2011002856A2 PCT/US2010/040552 US2010040552W WO2011002856A2 WO 2011002856 A2 WO2011002856 A2 WO 2011002856A2 US 2010040552 W US2010040552 W US 2010040552W WO 2011002856 A2 WO2011002856 A2 WO 2011002856A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- culture medium
- primary amine
- test sample
- butylamine
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
Definitions
- the present invention is directed to the neutralization and/or inactivation of antibiotics in a test sample or culture medium.
- the present invention is also directed to a method of culturing and detecting microorganisms that may be present in a test sample.
- Bottles such as those disclosed in U.S. Pat. Nos. 4,945,060; 5,094,955; and 5,162,229, herein incorporated by reference, have a culture medium and a sensor in the interior of the bottle that undergoes a detectable change due to the growth of microorganisms present in the bottle.
- the change in the sensor is monitored from outside the culture bottle through the transparent wall of the culture bottle, such as with a light emitter and detector as disclosed in, for example, U.S. Pat. Nos.
- Industrial samples such as pharmaceuticals and foods may also contain antimicrobials or preservatives that inhibit the growth of microorganisms. Additionally, when culture media is prepared, autoclaving of the media at very high temperatures under pressure can result in the formation of by-products toxic to microorganisms. Removal or neutralization of these inhibitory or bactericidal substances is necessary to detect microbial contamination.
- the resin and non- resinous adsorbents described include, aluminum oxide, colloidal native hydrated aluminum silicates, crystalline hydrated alkali-aluminum silicates, silica, siliceous frustules, fragments of various species of diatoms, amorphous carbon, ion exchange resins, non-functional polymeric resin adsorbents, polystyrene resin cross-linked with divinyl benzene and combinations thereof.
- the present invention provides a means for the neutralization or inhibition of antimicrobials in test samples, while helping to retain the components of the medium necessary to recover and detect microorganisms in a rapid manner.
- ⁇ -lactams e.g., carbapenems
- the present invention involves a means or method involving the use of one or more primary amine-containing compounds to neutralize, bind, inhibit or otherwise inactivate an antimicrobial substance (e.g., one or more antibiotics) in a growth or culture medium.
- an antimicrobial substance e.g., one or more antibiotics
- the present invention is directed to the neutralization, inhibition or inactivation of one or more antibiotics with one or more primary amine- containing compounds in culture medium (e.g., a blood culture).
- the present invention is also directed to a method for the neutralization and/or inactivation of an antimicrobial in a culture medium (e.g., a blood culture) comprising adding one or more primary amine-containing compounds to a culture medium which is capable of supporting growth of microorganisms, wherein said one or more primary amine-containing compounds are present in an amount effective neutralizes and/or inactivates any carbapenems present in said culture medium.
- a culture medium e.g., a blood culture
- the antimicrobial is a carbapenem.
- the primary amine is a non-thiol containing primary amine.
- the present invention is directed to a method for enhanced recovery and detection of microorganisms in culture, the method comprising: (a) preparing culture medium; (b) adding to the medium at least one primary amine -containing compound in amounts that are effective for neutralizing, binding or inhibiting antimicrobial substances in the culture medium; (c) inoculating the medium with a sample; and (d) incubating and determining the results.
- the antimicrobial is a carbapenem.
- the primary amine is a non-thiol containing primary amine.
- the present invention is directed to a method for the diagnosis of an infection caused by a microorganism, comprising the steps of: (a) obtaining a specimen sample or test sample for which the presence or absence of a microorganism is to be determined, and wherein said specimen or test sample may contain one or more antimicrobials that may interfere with the growth and/or detection of the microorganism; (b) adding said specimen sample or test sample to a culture medium, said culture medium comprising at least one primary amine-containing compound in an amount that is effective for neutralizing, binding or inhibiting said one or more antimicrobials; and (c) analyzing said culture for the presence of said microorganism, wherein detection of the presence of said microorganism indicates a positive diagnosis for said infection.
- the antimicrobial is a carbapenem.
- the primary amine is a non-thiol containing primary amine.
- detection of said microorganism comprises detection of the growth of said microorganism in said culture medium.
- the present invention is directed to a device for detecting microorganisms suspected of being in a specimen
- a sealable specimen container comprising an internal chamber in which the specimen may be cultured in a culture medium, said culture medium containing at least one primary amine-containing compound, wherein said primary amine-containing compound neutralizes and/or inactivates antibiotics that may be present in said specimen.
- the present invention is directed to a kit for detecting microorganisms in a test sample, the kit comprising: (1) a sealable specimen container, having an internal chamber comprising a culture medium and in which a test sample, for which the presence or absence of a microorganism is to be determined, may be cultured; and (2) a supplement comprising one or more primary amine-containing compounds.
- the supplement can be added to the culture medium contained in the sealable specimen container, thereby providing the one or more primary amine-containing compounds in an amount that is effective for neutralizing, binding or inhibiting any antimicrobials that may be present in said culture medium.
- a test sample can be added to the culture medium, concurrently with, or after addition of the supplement to the culture medium, the supplement providing the one or more primary amine- containing compounds in an amount that is effective for neutralizing, binding or inhibiting any antimicrobials that may be present in said test sample.
- Figure IA - is a Size Exclusion Chromatography (SEC) Chromatogram of imipenem in the presence of cysteine after a reaction time of 0 min.
- Figure IB - is a Size Exclusion Chromatography (SEC) Chromatogram of imipenem in the presence of cysteine after a reaction time of 20 min.
- Figure 1C - is a Size Exclusion Chromatography (SEC) Chromatogram of imipenem in the presence of cysteine after a reaction time of 60 min.
- Figure ID- is a Size Exclusion Chromatography (SEC) Chromatogram of imipenem in the presence of cysteine after a reaction time of 90 min.
- Figure 2A - is a Size Exclusion Chromatography (SEC) Chromatogram of imipenem, without cysteine after a reaction time of 0 min.
- Figure 2B - is a Size Exclusion Chromatography (SEC) Chromatogram of imipenem, without cysteine after a reaction time of 20 min.
- Figure 2C - is a Size Exclusion Chromatography (SEC) Chromatogram of imipenem, without cysteine after a reaction time of 60 min.
- Figure 2D - is a Size Exclusion Chromatography (SEC) Chromatogram of imipenem, without cysteine after a reaction time of 90 min.
- Figure 3 - is a boxplot showing the effect of cysteine on the recovery of S. aureus in the presence of imipenem.
- the present invention provides methods for detecting the presence of microorganisms in a specimen or test sample containing or suspected of containing microorganisms.
- the methods involve a chemical neutralization method involving the use of primary amine-containing compounds to neutralize, bind, inhibit or otherwise inactivate an antimicrobial substance (e.g., antibiotics) in a growth or culture medium.
- an antimicrobial substance e.g., antibiotics
- the present invention is directed to the neutralization, inhibition or inactivation of one or more antibiotics with a primary amine - containing compound in blood culture medium.
- the primary amine - containing compound may be a non-thiol containing compound and/or a hydroxylamine.
- Samples that may be tested by the methods of the invention include both clinical and non-clinical samples in which microorganism presence and/or growth is or may be suspected, as well as samples of materials that are routinely or occasionally tested for the presence of microorganisms.
- Test samples can typically range from about 0.5 ml to about 50 ml, from about 1 ml to about 10 ml, or from about 2 ml to about 5 ml.
- Clinical specimens or specimen samples that may be tested include any type of sample typically tested in clinical or research laboratories, including, but not limited to, blood, serum, plasma, blood fractions, joint fluid, urine, semen, saliva, feces, cerebrospinal fluid, gastric contents, vaginal secretions, tissue homogenates, bone marrow aspirates, bone homogenates, sputum, aspirates, swabs and swab rinsates, other body fluids, and the like.
- samples are obtained from a subject (e.g., a patient) having or suspected of having a microbial infection.
- the subject has or is suspected of having septicemia, e.g., bacteremia or fungemia.
- the sample may be a blood sample taken directly from the subject.
- Non-clinical samples that may be tested also include substances, encompassing, but not limited to, foodstuffs, beverages, pharmaceuticals, cosmetics, water (e.g., drinking water, non-potable water, and waste water), seawater ballasts, air, soil, sewage, plant material (e.g., seeds, leaves, stems, roots, flowers, fruit), blood products (e.g., platelets, serum, plasma, white blood cell fractions, etc.), donor organ or tissue samples, biowarfare samples, and the like.
- the method is also particularly well suited for real-time testing to monitor contamination levels, process control, quality control, and the like in industrial, commercial, and/or clinical settings.
- a first aspect of the invention relates to methods for the neutralization and/or inactivation of antibiotics using one or more primary amine-containing compounds.
- the method comprises adding one or more primary amine-containing compounds to a growth or culture medium in an effective amount to neutralize, bind, and/or inhibit one or more antibiotics present, or suspected of being present, in a test sample.
- the one or more primary amine-containing compounds can be added to the growth or culture media prior to, or concurrently with, innoculation of the growth or culture media with a test sample.
- a primary amine-containing compound provides a chemical means for neutralization of antimicrobials, whereby the primary amine interacts or binds with the ⁇ -lactam ring structure of the antibiotic.
- the primary amine may carry out a nucleophilic attack on the ⁇ -lactam ring forming a covalent complex leading to the inactivation and/or neutralization of the ⁇ -lactam antibiotic.
- the growth or culture media and test sample can be incubated for a sufficient time and at a sufficient temperature to allow for the growth and detection of any microorganism that may be present in the test sample. Growth can be detected by any known means in the art.
- growth can be detected using a BacT/ALERT ® or BacT/ALERT ® 3D systems (bioMerieux, Inc.).
- the time and temperature required for growth of the microorganism are largely species specific, but typically will be from about 1 hour to about 48 hours and from about 30 0 C. to about 42 0 C.
- an “effective amount” means the use of a sufficient amount of a compound to neutralize, bind, and/or inhibit the activity of one or more antibiotics present, or suspected of being present, in a test sample or culture media.
- An “effective amount” can be an amount sufficient to produce a measurable inhibition of one or more antibiotics present in a test sample or medium. Inhibition of antibiotics can be measured in vitro by high-performance liquid chromatography (HPLC), or by other methods known to one skilled in the art.
- HPLC high-performance liquid chromatography
- An “effective amount” can also be an amount sufficient to show detectable microorganism growth in a test sample or culture media containing an antibiotic whose activity would otherwise suppress or eliminate detectable growth.
- an “effective amount” may not need to be an amount that would totally eliminate the activity of one or more antibiotics present, or suspected of being present in the growth or culture media. Rather, in the practice of the present inevntion, the use of an "effective amount" of one or more primary amine-containing compounds in a growth or culture media allows for the growth or cultivation of microorganisms that would otherwise be surpressed or eliminated from the presence of one or more antibiotics that are neutralized, bound, and/or inhibited by the primary amine- containing compound, in accordance with the present invention.
- an "effective amount" of one or more primary amine-containing compounds is an amount allowing for a final concentration in the growth of culture media of from about 0.1 g/L to about 20 g/ L, from about 0.5 g/ L to about 10 g/ L, or from about 1 g/L to about 5 g/L.
- the present invention is a method for enhanced recovery and detection of microorganisms in culture, the method comprising: (a) preparing culture medium; (b) adding to the medium at least one primary amine-containing compound in amounts that are effective for neutralizing, binding or inhibiting antimicrobial substances in the culture medium; (c) inoculating the medium with a sample to be tested; and (d) incubating and determining the results.
- the present invention is also directed to a method for the neutralization and/or inactivation of a carbapenem in a blood culture comprising adding a primary amine-containing compound to a blood culture medium which is capable of supporting growth of microorganisms, wherein said primary amine- containing compound neutralizes and/or inactivates any carbapenems present in said culture medium.
- the present invention relates to a method for the diagnosis of an infection caused by a microorganism, comprising the steps of: (a) obtaining a test sample for which the presence or absence of a microorganism is to be determined, and wherein said test sample may contain one or more antimicrobials which may interfere with the growth and/or detection of the microorganism; (b) adding said test sample to a culture medium, said culture medium comprising at least one primary amine-containing compound in an amount that is effective for neutralizing, binding or inhibiting said one or more antibiotics; and (c) analyzing said culture for the presence of said microorganism (e.g., detection of said microorganism or the growth of said microorganism), wherein a finding of the presence of said microorganism indicates a positive diagnosis for said infection.
- a test sample for which the presence or absence of a microorganism is to be determined, and wherein said test sample may contain one or more antimicrobials which may interfere with the growth and/or detection of the microorganis
- the growth or culture media and test sample can be incubated for a sufficient time and at a sufficient temperature, as is well known to those skilled in the art, to allow for the growth and detection of any microorganism that may be present in the test sample.
- Growth can be detected by any known means in the art. For example, growth can be detected using a BacT/ALERT ® or BacT/ALERT ® 3D systems (bioMerieux, Inc.). Growth readings can be taken continuously or a give time intervals.
- any known antibiotic can be neutralized using the methods of the present invention.
- the present invention is directed to the use of a primary amine-containing compounds to neutralize and/or inactivate a ⁇ -lactam antibiotic
- ⁇ -lactam antibiotics are a broad class of antibiotics that include any antibiotic agent that contains a ⁇ - lactam nucleus in its molecular strucutre.
- ⁇ -lactam antibiotics include, but are not limited to, penicillins, penicillin derivatives, cephalosporins, monobactams, carbapenems, and ⁇ - lactamase inhibitors.
- primary amine-containing compounds can be used to neutralize and/or inactivate penicillin and penicillin derivative antibiotics.
- Penicillins are a class of ⁇ -lactam antibiotics known as penams.
- Penams are a group of antibiotics sharing a similar core skeleton (R-CgH 11 N 2 O 4 S, where R is a variable side chain).
- Penicillins and penicillin derivatives include, for example, benzathine penicillin, benzylpenicillin (penicillin G), phenoxymethylpenicillin (penicillin V), procaine penicillin, oxacillin, methicillin, nafcillin, cloxacillin, dicloxacillin, flucloxacillin, temocillin, amoxycillin, ampicillin, azlocillin, carbenixillin, mezlocillin, and piperacillin.
- penicillins and penicillin derivatives include, for example, benzathine penicillin, benzylpenicillin (penicillin G), phenoxymethylpenicillin (penicillin V), procaine penicillin, oxacillin, methicillin, nafcillin, cloxacillin, dicloxacillin, flucloxacillin, temocillin, amoxycillin, ampicillin, azlocillin, carbenixillin, mezlocill
- primary amine-containing compounds can be used to neutralize and/or inactivate cephalosporins and cephalosporin derivatives.
- Cephalosporins are a group of ⁇ -lactam antibiotics sharing a core skeleton comprising 7-aminocephalosporanic acid.
- Cephalosporins and cephalosporin derivatives include, for example, cephalexin, cephalothin, cefazolin, cefaclor, cefuroxime, cefamandole, cefotetan, cefoxitin, ceftrizxone, cefotaxime, cefpodoxime, ceftazidime, cefepime, and cefpirome.
- primary amine-containing compounds can be used to neutralize and/or inactivate carbapenem and carbapenem derivatives.
- Carbapenems are a class of ⁇ -lactam antibiotics with a broad spectrum of antibacterial activity, and have a structure that renders them resistant to ⁇ -lactamases.
- Carbapenems and carbapenem derivatives include imipenem, meropenem, ertapenem, doripenem, panipenem, betamipron, biapenem, and PZ-601.
- the carbapenems are somewhat structurally similar to the penicillins, but the sulfur atom in position 1 of the structure has been replaced with a carbon atom, and hence the name of the group, the carbapenems. Nevertheless, this seemingly subtle structural difference can lead to dramatic different effects in chemical and biological activity.
- primary amine-containing compounds can be used to neutralize and/or inactivate ⁇ -lactamase inhibitors and derivatives of ⁇ -lactamase inhibitors, ⁇ -lactamase inhibitors and derivatives include, for example, calvulanic acid, tazobactam and sulbactam.
- the primary amine-containing compound can be added to a growth or culture media.
- the primary amine- containing compound can be added directly to the media prior to, or concurrently, with inoculation of the medium with a sample to be tested.
- the primary amine-containing compound can be added directly to the sample to be tested, prior to the sample being added to the growth or culture medium.
- a suitable growth or culture medium provides the proper nutritional and environmental conditions for growth of microorganisms and should contain all the nutrients required by the microorganisms which are to be cultivated.
- a typical microbiological culture medium should contain water, a carbon source, a nitrogen source, vitamins, trace elements such as potassium, magnesium, calcium and iron, and minerals, such as sulfur and phosphorous. Typically, these needs are supplied from a number of sources.
- Other factors for suitable propagating conditions may include pH, temperature, aeration, salt concentration and osmotic pressure of the medium.
- a growth factor is an organic compound which a microorganism must contain in order to grow but which it is typically unable to synthesize.
- Many microorganisms when provided with the nutrients listed above, are able to synthesize all of the organic constituents of their protoplasm, including amino acids, vitamins, purines and pyrimadines, fatty acids and other compounds.
- each of these essential compounds can be synthesized by a discrete sequence of enzymatic reactions, where each enzyme is produced under the control of a specific gene.
- Required growth factors may include, but are not limited to, amino acids, vitamins, purines and pyrimadines, fatty acids and other required compounds for growth.
- the growth or culture media used in the practice of the present invention can be any known growth of culture media for the cultivation of microorganisms.
- the culture medium of the present invention comprises a liquid nutrient medium or nutrient broth.
- the culture medium or nutrient broth of the present invention typically comprises one or more known nutirents, for example, the culture medium may contain one or more carbon sources (e.g., glycerol), nitrogen sources (e.g., ammonia salts), sugars, salts (e.g., K + , Mg 2+ , Ca , Zn ), nutrients, and/or water.
- the culture medium of the present invention may further comprise one or more of potassium salts, sodium salts, sodium glutamate, sodium citrate, ammonium sulfate, pyridoxine, ferric ammonium citrate, magnesium sulfate, zinc sulfate, copper sulfate, biotin, calcium chloride, or combinations thereof.
- general purpose medias can be used, include, for example, tryptic soy broth, brain heart infusion broth, Columbia broth, and Brucella broth.
- any known primary amine-containing compound can be used in the practice of the present invention.
- one or more primary amine- containing compounds can be added to the growth or culture media prior to, or concurrently with, inoculation of the growth or culture media with a test sample.
- the primary amine-containing compound can be added as a supplement to the culture medium prior to the inoculation of the primary amine-containing culture medium with a sample to be tested.
- the primary amine-containing compound can be added directly to the test sample prior to inoculation of the culture medium with the primary amine- containing test sample.
- Useful primary amines include, but are not limited to, a primary amine of the formula R-NH 2 where R is a linear or branched alkyl, aryl, alkaryl, or aralkyl group having between about 1 and about 20 carbon atoms.
- R groups include, without limitation, methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, hexyls (linear or branched), hepyls, octyls, nonyls, decyls, phenyl, benzyl, methyl substituted phenyls, or mixtures or combinations thereof.
- the primary amine is a hydroxylamine.
- Exemplary primary amines may include methylamine, ethanolamine, trisamine, propylamine, 2-aminoheptane, 2-amino-2-methyl-l,3 propanediol, 2-amino-2-methyl-l-propanol, n- amylamine, benzylamine, 1 ,4-butanediamine, n-butylamine, cyclohexylamine, ethylamine, ethylenediamine, ⁇ -methylbenzylamine, phenethylamine, isopropylamine, butylamine, sec- butylamine, iso-butylamine, and tris(hydroxymethyl)aminomethane.
- organic primary amines may be preferred.
- Suitable organic primary amines may include aliphatic, cycloaliphatic, aliphatic/aromatic, aromatic amines, diamines and/or polyamines, such as methylamine, ethylamine, butylamine, stearylamine, aniline, halogen-substituted phenylamines (e.g., 4-chlorophenylamine), 1,4- diaminobutane, 1,6-diaminohexane, 1,8-diamino-hexane, l-amino-3,3,5-trimethyl-5- aminocyclohexane, lysine ethyl ester, lysine aminoethyl ester, 1,6,11 -triaminoundecane or 1,5-naphthylenediamine, 1 ,4-diaminobenzene, p-xylylenedi
- Preferred amines for the present invention are the diamines and polyamines of the diphenylmethane series (MDA, monomeric, oligomeric and polymeric amines), 2,4-, 2,6-diaminotoluene (TDA, toluoylenediamines), for example technical mixtures of 2,4-, 2,6-diaminotoluene (TDA, toluoylenediamines) in a weight ratio of 80:20, isophorone diamine and hexamethylenediamine.
- MDA diphenylmethane series
- TDA 2,4-, 2,6-diaminotoluene
- TDA toluoylenediamines
- MDI diisocyanatodiphenylmethane
- TDI toluene diisocyanate
- HDI hexamethylene diisocyanate
- IPDI isophorone diisocyanate
- the primary amine can be an amino acid.
- exemplary amino acids include, but are not limited to, alanine, arginine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine.
- hydroxylamines generally include compounds having the formula NH 2 OH, and salts thereof.
- Exemplified useful hydroxylamines include, but are not limited to, methanolamine, ethanolamine, propanolamine, butanolamine, pentanolamine, hexanolamine, heptanolamine, octanolamine, nonanolamine and decanolamine.
- Thiol groups or sulfhydryl groups tend to be scavengers of oxygen, and thus, may interfere with components of a growth or culture media and/or microorganism growth in a growth or culture media.
- the use of one or more non-thiol containing primary amines may be preferred.
- non- thiol containing primary amines may include any known primary amine-containing compounds that does not contain a thiol group.
- non-thiol containing primary amines include, but are not limited to, methylamine, ethanolamine, trisamine, propylamine, 2-aminoheptane, 2-amino-2-methyl-l,3 propanediol, 2-amino-2-methyl-l-propanol, n- amylamine, benzylamine, 1 ,4-butanediamine, n-butylamine, cyclohexylamine, ethylamine, ethylenediamine, ⁇ -methylbenzylamine, phenethylamine, isopropylamine, butylamine, sec- butylamine, iso-butylamine, and tris(hydroxymethyl)aminomethane.
- non-thiol containing amino acid may be preferred.
- Useful non-thiol containing amino acids include, but are not limited to, alanine, arginine, asparagine, aspartate, glutamate, glutamine, glycine, histidine, isoleucine, leucine, lysine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine.
- the primary amine can be bound to, or immobilized on, a solid support or a polymeric carrier, and the primary amine-support complex added to a culture medium or bottle, as discussed herein.
- the support may be any material on which a binding partner can be immobilized, such as nitrocellulose, silica, polystyrene, polypropylene, polyvinyl chloride, EVA, glass, carbon, glassy carbon, carbon black, carbon nanotubes or fibrils, platinum, palladium, gold, silver, silver chloride, iridium, or rhodium.
- the solid support can be, polymeric carriers, for example modified silica gel, glass, especially "controlled pore glass", polyester, polyamide, polyvinyl alcohol, polysiloxane, polystyrene or the like.
- useful solid supports may include, but are not limited to, silica and neutral macroporous resins such co-polymers of styrene and divinylbenzene.
- the growth or culture media may further comprise one or more adsorbents for the neutralization, inhibition and/or removal of additional antimicrobial substances that may be present in a test sample.
- antimicrobial substances include, among others, antibiotics, antibiotics in body fluid samples, preservatives, bacteriostats, bactericides, and any toxic by-products produced during the preparation of culture media.
- Antimicrobial substances also include naturally occurring components in blood such as complement and antibodies.
- adsorbent for the purposes of this application, includes all adsorbent materials that neutralize, bind, and inhibit antimicrobial substances. These adsorbents include resins and non-resinous adsorbents as defined in U.S. Pat. Nos. 4,145,304; 4,632,902; 5,162,229; and 5,314,229.
- resin is a subclass of adsorbents, and is further defined to include naturally occurring and synthetic resins, for example ion exchange resins, nonfunctional polymeric resin adsorbents and, in particular, polystyrene resins cross-linked with divinyl benzene.
- Useful resins can include, but are not limited to, those disclosed in U.S. Pat. Nos. 4,145,304 and 4,632,902.
- useful resins may include sodium, hydrogen and ammonium charged cation exchange resins such as: BIO REX AG 5OW— X 2 , X 4 , X 6 , Xs, X 10 , X 12 , and X 16 from BIO-RAD Laboratories, DOWEX 5OW - X 2 , X 4 , X 6 , X 8 , X 10 , X12, and X 16 from Dow Chemical Company and Rexyn 101 from Fisher Scientific Co., all of which are strong acid polystyrene resins having SO 3" functional group.
- Useful non-functional resins may include XAD resins manufactured by Rohm & Haas and SM resins sold by BioRad.
- chloride, formate, acetate and hydroxide, charged anion exchange resins have generally been found to be suitable.
- chloride charged anionic exchange resins in combination with adsorbent resins sold under the following trademarks may be effective in the practice of the invention.
- DOWEX 1-X8 from Dow Chemical Company, DUOLITE A- 109 from Diamond Shamrock Company and AMBERLITE IRA400 from Rohm & Haas, all of which are strong base resins having polystyrene quaternary ammonium functional groups; DUOLITE A-7 from Diamond Shamrock Company and AMBERLITE IR45 from Rohm & Haas, which are weakly basic and have tertiary amine functional groups.
- the cation and anion exchange resins may preferably be used in combination with a non-functional resin such as the XAD resins from Rohm & Haas and SM resin from BioRad, particularly XAD-4 resin which is a nonfunctional copolymer of styrene and divinyl benzene.
- a non-functional resin such as the XAD resins from Rohm & Haas and SM resin from BioRad, particularly XAD-4 resin which is a nonfunctional copolymer of styrene and divinyl benzene.
- non-resinous adsorbents are another subclass of adsorbents and are defined as naturally occurring and synthetic non-resin adsorbents and molecular sieves that can be used for clarifying, deodorizing, decolorizing, and filtering.
- non-resinous adsorbents are the same as those used during the production of antibiotics to remove antibiotics from culture medium growing antibiotic-producing bacteria.
- Useful non- resinous adsorbents include those disclosed in U.S. Pat. Nos. 5,162,229 and 5,314,229.
- useful non-resinous adsorbents include various forms of 1) aluminum oxide (alumina), 2) colloidal native hydrated aluminum silicates (clays), such as bentonite, kaolin, and fuller's earth, 3) crystalline hydrated alkali-aluminum silicates (sodium or calcium zeolites), 4) silica (silica gel, silica beads) such as Davisil, 5) siliceous frustules and fragments of various species of diatoms (infusorial earth, diatomaceous earth) such as CeliteTM (Manville Products Corporation, Denver, Colo., USA) and 6) amorphous carbon (in particular, activated carbon) such as Carboraffin, NoritTM (American Norit Company Inc., Jacksonville, FIa., USA), Opocerbyl, and Ultracarbon.
- amorphous carbon in particular, activated carbon
- Naturally occurring adsorbent activated charcoal which has been used to prevent the lethal effects of oxidation in transport media and growth media, can also be used. This media has been used for the transport of fastidious organisms such as Neisseria gonorrhoeae and the cultivation of Legionella species.
- Non-resinous adsorbents do not require pre -treatment with a surfactant in order to function. Treatment with surfactants may even decrease the adsorptive capabilities of these materials.
- adsorbents at an appropriate ratio to medium may also remove toxic by-products produced in autoclaved media and still provide an optimal nutritious culture medium while maintaining the ability to neutralize antimicrobial substances.
- the resins and/or non-resinous adsorbents may be present in the culture media from about 0.1 g to about 10 g per bottle.
- the present adsorbents are not limited to use in a device or culture bottle. They may be added to any standard culture media, which is then inoculated with a sample, incubated at the correct temperature for an appropriate time for the type of sample being tested, while usually shaken or rocked in order to expose more surface area of the adsorbent to the liquid, to better contact any organisms present with nutrients and to avoid areas of high concentration of metabolic by-products.
- the temperatures and time periods needed for the determination of microorganism growth are well known to those skilled in the art and vary somewhat among different types of organisms.
- the present invention is directed to a device for detecting microorganisms suspected of being in a test sample or specimen
- a sealable container comprising an internal chamber in which the test sample or specimen may be cultured in a growth or culture medium, said growth or culture medium containing at least one primary amine-containing compound, wherein said primary amine -containing compound neutralizes, binds and/or inactivates one or more antibiotics (e.g., carbapenems) present in said specimen.
- the device is a blood culture bottle, as described, for example, in U.S. Pat. Nos. 5,094,955 and 5,162,229.
- a test sample is introduced into the device, and the device is incubated until either positive growth is detected or, generally, until 5-7 days have passed and no growth is detected.
- the primary amine-containing compound can be included in a supplement that can be added to the culture medium prior to, or concurrently with inoculation of the culture medium with the sample to be tested.
- the primary amine-containing supplement can be added directly to the test sample, prior to inoculation of the bottle and culture media with the primary amine- containing test sample.
- the supplement may further comprise one or more nutrients and/or components known to those of skill in the art as being beneficial to the cultivation of microorganisms.
- the supplement of the present invention may additionally comprise of one or more sugars, carbon sources, nitrogen sources, minerals, salts, amino acids, vitamins, purines and pyrimadines, fatty acids and other compounds.
- the present invention is directed to a kit for detecting microorganisms in a test sample, the kit comprising: (1) a sealable specimen container, having an internal chamber comprising a culture medium and in which a test sample, for which the presence or absence of a microorganism is to be determined, may be cultured; and (2) a supplement comprising one or more primary amine-containing compounds.
- the supplement can be added to the culture medium contained in the sealable specimen container, thereby providing the one or more primary amine-containing compounds in an amount that is effective for neutralizing, binding or inhibiting any antimicrobials that may be present in said culture medium.
- a test sample can be added to the culture medium, concurrently with, or after addition of the supplement to the culture medium, the supplement providing the one or more primary amine - containing compounds in an amount that is effective for neutralizing, binding or inhibiting any antimicrobials that may be present in said test sample.
- the supplement of the kit further comprises a second container or vial comprising the one or more primary amine -containing compounds.
- the second container or vial comprises the one or more primary amine-containing compounds suspended in a stabilization buffer. Stabilization buffers are well known to those skilled in the art.
- the one or more primary amine-containing compounds present in said container or vial can be lyophilized.
- the lyophilized one or more primary amine-containing compounds may be re-suspended in a re-suspension buffer or stabilization buffer prior to being added to the culture medium in the specimen container.
- the kit of the present invention may further provide a third container or vial comprising said re-suspension or stabilization buffer.
- microorganisms can be determined by detecting or measuring changes in the pH of the specimen or the production of CO 2 within a specimen using a disposable sensor affixed to the interior surface of the container, as described, for example, in U.S. Pat. Nos. 4,945,060 and 5,164,796, which are incorporated herein by reference.
- microorganisms can be detected in the presence of interfering materials, such as large concentrations of red blood cells, through non-radiometric and non-invasive means.
- the level of pH and/or CO 2 within the specimen changes, the light reflecting and/or absorbing characteristics of the disposable sensor will alter correspondingly.
- the quantity of alteration of the reflective properties of the sensor is detected by an emission and receiving mechanism which supplies signals to a device for monitoring the quantity of visible reflection/absorption and the rate of change.
- the rate and quantity is then analyzed to predict and determine the presence of microbial growth within the specimen or sample.
- the sensor can be sampled and/or monitored continuously or at frequent time intervals allowing for the collection of a detailed characteristic of the quantity and rate of sensor change.
- the sensor means may comprise a membrane and an indicator medium, the indicator medium being selected for its ability to exhibit a detectable change when exposed to products of an organism's metabolic activity.
- the changes in the appearance of the sensor means can be continuously monitored from the exterior of the container through a transparent section of the container.
- This device or blood culture bottle may also include materials in the culture medium such as the resinous materials, as described in U.S. Pat. Nos. 4,145,304 and 4,632,902, and non-resinous adsorbent materials, as described in U.S. Pat. Nos. 5,162,229 and 5,314,229, or combinations thereof, that neutralize, bind, or inhibit any other antimicrobial substances that may be present in the test sample of culture media.
- the resins and/or non-resinous adsorbents may be present in the device from about 0.1 g to about 1O g per bottle.
- a stock solution of USP grade imipenem was prepared by dissolving 1.8 grams in 10 mL of 14 mM K 2 HPO 4 (pH 7.0) in a glass screw cap tube.
- a stock solution of cysteine was prepared by dissolving 31.3 mg in 1.08 mL of 14 mM K 2 HPO 4 in a 2 mL polypropylene centrifuge tube.
- An imipenem reaction without cysteine was prepared by combining 2.2 mL of the stock imipenem solution with 7.8 mL of 14 mM K 2 HPO 4 to a final concentration of 40 ⁇ g/mL. The total 10 mL volume was then added to a BacT/ Alert culture bottle containing resin adsorbents. The bottle was briefly agitated to mix and 500 ⁇ L of volume was removed for analysis. The bottle was then placed in a BacT/ Alert ® 3D instrument (bioMerieux, Inc., Missouri, USA) at 36 0 C and additional 500 ⁇ L samples were removed at 20, 40, 60 and 90- minute intervals for analysis (see Figures 2A-2D).
- An imipenem reaction with cysteine was prepared by combining 2.2 mL of the stock imipenem solution with 7.8 mL of 14 mM K 2 HPO 4 to a final concentration of 40 ⁇ g/mL. The total 10 mL volume was then added to a BacT/ Alert culture bottle containing resin adsorbents. A 500-uL sample of the cysteine stock solution was then added to a final cysteine concentration of 4 mM. The bottle was briefly agitated to mix and 500 ⁇ L of volume was removed for analysis.
- reaction samples were analyzed on an HPLC equipped with a BioSepTM-SEC- 2000 (Phenomenex) size exclusion HPLC column with a mobile phase of 100 mM Na 2 HPO 4 , ph 6.5 at a 1-mL/minute flow rate. Reactions were monitored at 300 nm and the total analysis time per sample was 16 minutes.
- the bottle containing both imipenem and cysteine showed a reduction of imipenem of approximately 70%, 85%, 89% and 91% after 20, 40, 60, and 90 minutes, respectively (see Table 1). However, after 90 minutes the bottle containing only imipenem showed no reduction in imipenem (see Figure Table 2).
- An imipenem solution was prepared by dissolving 4.0 mg of imipenem into 100 mL of phosphate buffered saline (PBS), pH 7.0, and sterile filtered through a 0.2 ⁇ filter.
- Cysteine was prepared by dissolving 300 mg into 10 mL PBS and sterile filtered through a 0.2 ⁇ filter to achieve a final concentration in BacT/ Alert ® bottles (bioMerieux Inc, Missouri, USA) of 4 mM with the addition of 500 ⁇ L.
- a culture of S. aureus was prepared after overnight incubation to a final concentration of 30-300 CFU (colony forming units)/500 ⁇ L.
- BacT/ Alert ® culture bottles (bioMerieux Inc, Missouri, USA) containing resin adsorbents were prepared for evaluation in triplicate as follows:
- Growth controls were prepared by adding 10 mL of sterile filtered PBS alone or 10 mL of sterile filtered PBS plus 500 ⁇ L of cysteine solution.
- a control for the imipenem activity was prepared by adding 10 mL of imipenem solution.
- the imipenem/cysteine reaction was prepared by adding 10 mL of imipenem solution plus 500 ⁇ L of cysteine solution.
- Each bottle received 500 ⁇ L of the S. aureus culture and was then placed in a BacT/Alert 3D ® instrument (bioMerieux Inc, Missouri, USA) at 36 0 C and monitored for growth over five days.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES10794689T ES2818374T3 (en) | 2009-07-01 | 2010-06-30 | Method of neutralizing antibiotics in a culture medium |
EP10794689.9A EP2449130B8 (en) | 2009-07-01 | 2010-06-30 | Method for neutralization of antibiotics in a culture medium |
CA2766600A CA2766600C (en) | 2009-07-01 | 2010-06-30 | Method for neutralization of antibiotics in a culture medium |
AU2010266341A AU2010266341B2 (en) | 2009-07-01 | 2010-06-30 | Method for neutralization of antibiotics in a culture medium |
JP2012517880A JP5774586B2 (en) | 2009-07-01 | 2010-06-30 | Method for neutralizing antibiotics in culture media |
EP20193065.8A EP3763809A1 (en) | 2009-07-01 | 2010-06-30 | Method for neutralization of antibiotics in a culture medium |
CN2010800297198A CN102656275A (en) | 2009-07-01 | 2010-06-30 | Method for neutralization of antibiotics in a culture medium |
BRPI1015021 BRPI1015021B1 (en) | 2009-07-01 | 2010-06-30 | Method for neutralizing antibiotics in a culture medium |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26995309P | 2009-07-01 | 2009-07-01 | |
US61/269,953 | 2009-07-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011002856A2 true WO2011002856A2 (en) | 2011-01-06 |
WO2011002856A3 WO2011002856A3 (en) | 2012-05-31 |
Family
ID=43411718
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/040552 WO2011002856A2 (en) | 2009-07-01 | 2010-06-30 | Method for neutralization of antibiotics in a culture medium |
Country Status (9)
Country | Link |
---|---|
US (3) | US8420346B2 (en) |
EP (2) | EP2449130B8 (en) |
JP (2) | JP5774586B2 (en) |
CN (2) | CN102656275A (en) |
AU (1) | AU2010266341B2 (en) |
BR (1) | BRPI1015021B1 (en) |
CA (1) | CA2766600C (en) |
ES (1) | ES2818374T3 (en) |
WO (1) | WO2011002856A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2993900B1 (en) * | 2012-07-27 | 2016-03-25 | Biomerieux Sa | PROCESS FOR THE DETECTION OF OXA-48 CARBAPENEMASES PRODUCTION BACTERIA |
WO2015140802A2 (en) | 2014-03-20 | 2015-09-24 | Technion Research & Development Foundation Limited | Delivery system comprising a proteolytic enzyme or effector thereof for use in a method for oral treatment and uses thereof |
KR101936047B1 (en) * | 2018-03-14 | 2019-01-08 | 주식회사 이디에스 | Door frame assembly structure of door frame |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4145304A (en) | 1977-12-02 | 1979-03-20 | Melnick Joseph L | Resin and method for removing antimicrobials from body fluids |
US4632902A (en) | 1981-08-20 | 1986-12-30 | Becton, Dickinson And Company | Method for detecting biological activity in a body fluid |
US4945060A (en) | 1988-03-15 | 1990-07-31 | Akzo N. V. | Device for detecting microorganisms |
US5074505A (en) | 1990-06-01 | 1991-12-24 | Akzo N.V. | Support attachment for holding bottles within a bottle block |
US5094955A (en) | 1988-03-15 | 1992-03-10 | Akzo N.V. | Device and method for detecting microorganisms |
US5162229A (en) | 1988-03-15 | 1992-11-10 | Akzo N.V. | Device and method for enhanced recovery and detection of microbial growth in the presence of antimicrobial substances |
US5164796A (en) | 1988-03-15 | 1992-11-17 | Akzo N.V. | Apparatus and method for detection of microorganisms |
US5217876A (en) | 1988-03-15 | 1993-06-08 | Akzo N.V. | Method for detecting microorganisms |
US5314229A (en) | 1991-11-19 | 1994-05-24 | Toyota Jidosha Kabushiki Kaisha | Front body structure |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3497504A (en) * | 1968-07-10 | 1970-02-24 | Lilly Co Eli | Removal of penicillins from cephalosporins |
US4221871A (en) * | 1970-12-16 | 1980-09-09 | Rohm And Haas Company | Reticular crosslinked monovinylidene N-heterocyclic copolymer |
US4174277A (en) * | 1977-12-02 | 1979-11-13 | Melnick Joseph L | Resin and method for removing antimicrobials from body fluids |
US4212948A (en) * | 1978-10-18 | 1980-07-15 | J. K. And Susie L. Wadley Research Institute And Blood Bank | Apparatus for detecting microbial pathogens employing a cushioning agent |
US5624814A (en) * | 1981-08-20 | 1997-04-29 | Becton Dickinson And Company | Culture medium and method for culturing body fluids containing antibiotics |
JPS59106289A (en) * | 1982-12-11 | 1984-06-19 | Terumo Corp | Multi-layered tool and device for inspecting culture of microorganism |
CA1264275A (en) * | 1985-09-04 | 1990-01-09 | Wadley Technologies, Inc. | Stabilization of specimens for microbial analysis |
US5518895A (en) * | 1990-02-15 | 1996-05-21 | Akzo N.V. | Device for detecting microorganisms using piezoelectric means |
US5858769A (en) * | 1989-05-15 | 1999-01-12 | Akzo Nobel N.V. | Device for detecting microorganisms |
US5070017A (en) * | 1990-12-11 | 1991-12-03 | General Electric Company | Method for biodegrading bisphenol alkanes |
AU668023B2 (en) * | 1993-02-11 | 1996-04-18 | Dsm Ip Assets B.V. | Unit for the detection of residues of antibacterial compounds in liquids |
WO1996023901A1 (en) * | 1995-02-01 | 1996-08-08 | Gist-Brocades B.V. | A rapid microbiological test for the detection of antibacterial compounds |
ES2294787T3 (en) * | 1995-06-05 | 2008-04-01 | Biomerieux, Inc. | DEVICE AND METHOD FOR DETECTING MICROORGANISMS. |
US6596532B1 (en) * | 1997-12-12 | 2003-07-22 | BIOMéRIEUX, INC. | Device for isolation and surface culture of microorganisms from bulk fluids |
GB0024203D0 (en) * | 2000-10-03 | 2000-11-15 | Peptide Therapeutics Ltd | Stabilisation of plasmid inheritance in bacteria |
US7291480B2 (en) * | 2002-03-13 | 2007-11-06 | Black Jennifer A | Device and method for detecting antibiotic-inactivating enzymes |
US20060035310A1 (en) * | 2004-08-13 | 2006-02-16 | Millipore Corporation | Media for recovery of microorganism in the presence of antibiotics |
WO2006047517A2 (en) * | 2004-10-26 | 2006-05-04 | University Of Maryland Baltimore | Live attenuated bacterial vaccine to reduce or inhibit carriage and shedding of enterohemorrhagic escherichia coli in cattle |
WO2008133659A2 (en) | 2006-11-29 | 2008-11-06 | Tufts University | Eschericia coli mutants and methods of use thereof |
US20090123960A1 (en) * | 2007-11-09 | 2009-05-14 | Becton, Dickinson And Company | Method for Removing Antibiotics From Blood Culture Samples |
CN101565728A (en) * | 2008-04-21 | 2009-10-28 | 曲奕 | Nutritional digestive juice for chlamydia neutralization |
CN101353622A (en) * | 2008-05-28 | 2009-01-28 | 天津市康赛生物技术有限公司 | Blood enriched culture bottle for full automatic blood culture system and preparation thereof |
-
2010
- 2010-06-30 AU AU2010266341A patent/AU2010266341B2/en active Active
- 2010-06-30 JP JP2012517880A patent/JP5774586B2/en active Active
- 2010-06-30 EP EP10794689.9A patent/EP2449130B8/en not_active Revoked
- 2010-06-30 CN CN2010800297198A patent/CN102656275A/en active Pending
- 2010-06-30 CA CA2766600A patent/CA2766600C/en active Active
- 2010-06-30 BR BRPI1015021 patent/BRPI1015021B1/en active IP Right Grant
- 2010-06-30 CN CN201710610246.4A patent/CN107312714A/en active Pending
- 2010-06-30 EP EP20193065.8A patent/EP3763809A1/en active Pending
- 2010-06-30 WO PCT/US2010/040552 patent/WO2011002856A2/en active Application Filing
- 2010-06-30 ES ES10794689T patent/ES2818374T3/en active Active
- 2010-06-30 US US12/827,241 patent/US8420346B2/en active Active
-
2013
- 2013-02-21 US US13/772,965 patent/US8603770B2/en active Active
- 2013-11-01 US US14/069,576 patent/US8911962B2/en active Active
-
2015
- 2015-07-01 JP JP2015132841A patent/JP6049812B2/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4145304A (en) | 1977-12-02 | 1979-03-20 | Melnick Joseph L | Resin and method for removing antimicrobials from body fluids |
US4632902A (en) | 1981-08-20 | 1986-12-30 | Becton, Dickinson And Company | Method for detecting biological activity in a body fluid |
US4945060A (en) | 1988-03-15 | 1990-07-31 | Akzo N. V. | Device for detecting microorganisms |
US5094955A (en) | 1988-03-15 | 1992-03-10 | Akzo N.V. | Device and method for detecting microorganisms |
US5162229A (en) | 1988-03-15 | 1992-11-10 | Akzo N.V. | Device and method for enhanced recovery and detection of microbial growth in the presence of antimicrobial substances |
US5164796A (en) | 1988-03-15 | 1992-11-17 | Akzo N.V. | Apparatus and method for detection of microorganisms |
US5217876A (en) | 1988-03-15 | 1993-06-08 | Akzo N.V. | Method for detecting microorganisms |
US5074505A (en) | 1990-06-01 | 1991-12-24 | Akzo N.V. | Support attachment for holding bottles within a bottle block |
US5314229A (en) | 1991-11-19 | 1994-05-24 | Toyota Jidosha Kabushiki Kaisha | Front body structure |
Non-Patent Citations (3)
Title |
---|
"Imipenem Susceptibility Powder (N-Formimidoyl thienamycin monohydrate)", MSD, April 1991 (1991-04-01), pages 1 - 3, XP055258192 |
KAHAN ET AL.: "Thienamycin, a new beta-lactam antibiotic. I. Discovery, taxonomy, isolation and physical properties", THE JOURNAL OF ANTIBIOTICS, vol. 32, no. 1, January 1979 (1979-01-01), pages 1 - 12, XP055258190 |
MCLEOD ET AL.: "Gentamicin assay in the presence of imipenem", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, vol. 17, no. 6, June 1986 (1986-06-01), pages 828 - 829, XP055258191 |
Also Published As
Publication number | Publication date |
---|---|
JP5774586B2 (en) | 2015-09-09 |
WO2011002856A3 (en) | 2012-05-31 |
JP2012531899A (en) | 2012-12-13 |
EP2449130A2 (en) | 2012-05-09 |
ES2818374T3 (en) | 2021-04-12 |
CA2766600A1 (en) | 2011-01-06 |
CA2766600C (en) | 2022-11-08 |
AU2010266341A1 (en) | 2012-02-02 |
BRPI1015021B1 (en) | 2019-12-10 |
JP2015211686A (en) | 2015-11-26 |
JP6049812B2 (en) | 2016-12-21 |
US20140234889A1 (en) | 2014-08-21 |
CN102656275A (en) | 2012-09-05 |
US8420346B2 (en) | 2013-04-16 |
EP3763809A1 (en) | 2021-01-13 |
US20130164822A1 (en) | 2013-06-27 |
US20110003329A1 (en) | 2011-01-06 |
CN107312714A (en) | 2017-11-03 |
EP2449130B1 (en) | 2020-09-09 |
EP2449130B8 (en) | 2020-11-04 |
AU2010266341B2 (en) | 2015-12-03 |
US8603770B2 (en) | 2013-12-10 |
US8911962B2 (en) | 2014-12-16 |
BRPI1015021A2 (en) | 2019-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3169269B2 (en) | Apparatus and method for enhancing recovery and detection of growing microorganisms in the presence of antimicrobial substances | |
JPH06210167A (en) | Adsorbent composition and its preparation | |
US8911962B2 (en) | Method for neutralization of antibiotics in a culture medium | |
US20090123960A1 (en) | Method for Removing Antibiotics From Blood Culture Samples | |
RU2460774C1 (en) | Nutrient medium for legionella cultivation | |
EP3368681B1 (en) | Assay for determining antibiotics in waste | |
RU2410437C1 (en) | Method of determining bacteriostatic, bactericidal and stimulating effect of antibiotic on microorganism | |
RU2299440C1 (en) | Determination of bacterial histidine decarboxylase activity | |
Serheed et al. | Detection of Reverse Osmosis Filters Efficiency in Drinking Water | |
RU2460775C1 (en) | Enriched nutrient medium for legionella cultivation | |
Boˆle et al. | Utilizing ultrafiltration to remove alkaline phosphatase from clinical analyzer water | |
CN113462739A (en) | Method and kit for detecting substance promoting antibiotic sterilization efficiency improvement | |
CN109988733A (en) | A kind of streptococcus specific solid medium, preparation method and applications | |
Jebur et al. | Antimicrobial Resistance Patterns and Metallobeta-lactamases Producing of Imipenem Resistant Pseudomonas aeruginosa Isolated from Clinical Samples of Iraqi Patients | |
US20140349325A1 (en) | Method and medium for detecting the presence or absence of an antibiotic resistant pathogenic staphylococci in a test sample |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080029719.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10794689 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012517880 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2766600 Country of ref document: CA Ref document number: 2010266341 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 661/CHENP/2012 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010794689 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2010266341 Country of ref document: AU Date of ref document: 20100630 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI1015021 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: PI1015021 Country of ref document: BR Kind code of ref document: A2 Effective date: 20111227 |